# CX3CR1+T Cell Predict Immunotherapy Efficacy

> **NCT06054152** · — · COMPLETED · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 150 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PD-1 inhibitor based immunotherapy

## Key facts

- **NCT ID:** NCT06054152
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-10
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-06-20
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06054152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06054152, "CX3CR1+T Cell Predict Immunotherapy Efficacy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06054152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*